Voya Investment Management LLC purchased a new stake in shares of Stemline Therapeutics, Inc. (NASDAQ:STML) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,069 shares of the biopharmaceutical company’s stock, valued at approximately $102,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in STML. Nationwide Fund Advisors boosted its holdings in shares of Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 855 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $147,000. Alliancebernstein L.P. acquired a new position in shares of Stemline Therapeutics during the second quarter valued at $178,000. UBS Group AG boosted its holdings in shares of Stemline Therapeutics by 130.0% during the first quarter. UBS Group AG now owns 26,945 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 15,232 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Stemline Therapeutics by 18.5% during the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 4,280 shares during the period. 46.54% of the stock is owned by institutional investors.

STML has been the subject of several analyst reports. Cowen Inc reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Stemline Therapeutics in a report on Tuesday, September 12th. Finally, ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $33.40.

Stemline Therapeutics, Inc. (NASDAQ:STML) opened at $14.45 on Friday. Stemline Therapeutics, Inc. has a 1-year low of $5.50 and a 1-year high of $15.15.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/voya-investment-management-llc-invests-102000-in-stemline-therapeutics-inc-stml/1725398.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics, Inc. (NASDAQ:STML).

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.